Nightstar Therapeutics PLC (NASDAQ:NITE)

19.75
Delayed Data
As of Jul 20
 +0.03 / +0.15%
Today’s Change
10.01
Today|||52-Week Range
24.94
+50.53%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$570.9M

Company Description

Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.

Contact Information

Nightstar Therapeutics PLC
9-10 Midford Place
London Greater London W1T 5BJ
P:442076112077
Investor Relations:

Employees

Shareholders

Mutual fund holders4.70%
Other institutional22.18%
Individual stakeholders--

Top Executives

David A. FellowsChief Executive Officer & Director
Senthil SundaramChief Financial Officer
Aniz GirachChief Medical Officer
Gregory RobinsonChief Scientific Officer
Tu Yen OngChief Development Officer